帕金森病精神病患者医疗资源利用模式：使用匹莫范色林或其他非典型抗精神病药的医保受益人分析

数据集获取（Figshare）

• 源站标题：Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics
• DOI：10.6084/m9.figshare.21718252.v1
• 发布日期：2022-12-13
• 文件数：1 个
• 文件总体积：23.97 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Health_care_resource_utilization_patterns_among_patients_with_Parkinson_s_disease_psychosis_analysis_of_Medicare_beneficiaries_treated_with_pimavanserin_or_other-atypical_antipsychotics/21718252

命令行下载

curl -L -o "ijme_a_2152600_sm9220.odt" "https://ndownloader.figshare.com/files/38538202"

文件清单

• ijme_a_2152600_sm9220.odt（23.97 KB）

文件总体积 23.97 KB（源站 API 实测）。

数据说明

Pimavanserin (PIM) is the only FDA-approved atypical antipsychotic (AAP) for hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). Comparative real-world analyses demonstrating its benefits are needed.
To evaluate health care resource utilization (HCRU) outcomes among PDP patients treated with PIM vs. other-AAPs.
Retrospective cohort analysis of Parts A, B, and D claims from 100% Medicare sample from 01 January 2013–31 December 2019 was conducted. PDP Patients initiating (i.e. index date) continuous monotherapy (PIM vs. other-AAPs) for ≥12-months during 01 January 2014–31 December 2018 without 12-months pre-index AAP use were selected after 1:1 propensity score matching (PSM) on 31 variables (sex, race, region, age, and 27 Elixhauser comorbidities). HCRU outcomes included: annual all-cause and psychiatric hospitalization (short-term stay, long-term stay, and SNF-stay [skilled nursing facility]) rates, annual all-cause and psychiatric-ER visit rates, mean per-patient-per-year (PPPY) hospitalizations, and average length of stay (ALOS). PIM and other-AAPs were compared using generalized linear models (GLM) controlled for demographic characteristics, comorbidities, coexisting-dementia, and coexisting insomnia.
Of 12,164 PDP patients, 48.41% (n = 5,889) were female, and mean age was 77 (±8.14) years. Among 1:1 matched patients (n = 842 in each), 37.8% (n = 319) on PIM vs. 49.8% (n = 420) on other-AAPs (p n = 286) vs. 46.2% (n = 389) and 20.2% (n = 170) vs. 31.8% (n = 267) (p n = 81) of PIM vs. 14.6% (n = 123) of other-AAPs patients had ≥1 psychiatric hospitalization (p n = 519) vs. 69.4% (n = 584) and 5.2% (n = 43) vs. 10.2% (n = 86) (p In this analysis of PDP patients, PIM monotherapy resulted in nearly 12% and 7% lower all-cause hospitalizations and ER visits vs. other-AAPs.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.21718252.v1（source: https://tandf.figshare.com/articles/dataset/Health_care_resource_utilization_patterns_among_patients_with_Parkinson_s_disease_psychosis_analysis_of_Medicare_beneficiaries_treated_with_pimavanserin_or_other-atypical_antipsychotics/21718252）。